(ZEPP) Zepp Health - Ratings and Ratios

Zepp Health Corporation (NYSE:ZEPP), formerly known as Huami Corporation, is a global leader in smart wearable technology and health-focused innovations. The company operates through two primary business segments: Self-Branded Products and Others, and Xiaomi Wearable Products. Its consumer-facing brands, including Amazfit, Zepp Clarity, and Zepp Aura, cater to users seeking to enhance their health, fitness, and wellness journeys through advanced wearable devices.

The companys proprietary Zepp Digital Management Platform serves as the backbone of its ecosystem, integrating Zepp OS, AI-driven chips, biometric sensors, and sophisticated data algorithms. This platform delivers cloud-based, 24/7 insights, enabling users to track and achieve their wellness goals effectively. Zepp Healths product portfolio includes smart bands, watches, modules, scales, and accessories, as well as smart hearables, sportswear, home fitness equipment, and smart watch accessories. The Zepp Life and Zepp mobile apps provide detailed charts and graphs to analyze activity and biometric data, offering a holistic view of user health metrics.

Zepp Health Corporation, founded in 2013 and headquartered in Hefei, China, distributes its products under the Amazfit and Zepp brands across approximately 90 countries. The company rebranded from Huami Corporation to Zepp Health Corporation in February 2021 to align with its expanded focus on health and wellness technologies.

3-Month Forecast:

Based on the provided and , the following insights can be derived for the next three months:

Technical Outlook: The stock is currently trading below its SMA 20 (2.86), SMA 50 (2.89), and SMA 200 (2.95), indicating potential oversold conditions. The Average True Range (ATR) of 0.20 suggests moderate volatility, which may persist in the near term. If the stock breaches its SMA 50 level, it could signal a short-term recovery.

Fundamental Outlook: With a market cap of $45.97M and a P/S ratio of 0.19, the company is undervalued relative to its peers. The forward P/E of 3.12 indicates expectations of future earnings growth. However, the negative RoE of -66.32 raises concerns about profitability. Improvements in operational efficiency and revenue growth will be critical for shareholder value appreciation.

Overall, the stock is likely to remain range-bound in the near term, with potential upside driven by fundamental improvements and technical breakout above key moving averages.